Nortolan (Nimodipine)

Nimodipine, the active ingredient in Nortolan, is a calcium channel blocker presented as an oral formulation for oral use. It is employed to prevent cerebral vasospasm after subarachnoid hemorrhage and to address cognitive impairment linked to cerebrovascular disease.

GNH USA supplies Nortolan as a licensed, GDP‑compliant international pharmaceutical product serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and offering comprehensive logistics support for global distribution.

Nimodipine acts on cerebral vasculature to reduce vasospasm and improve cerebral perfusion in relevant conditions.

- Subarachnoid hemorrhage: prevents cerebral vasospasm and reduces risk of delayed ischemic neurological deficits. - Delayed ischemic neurological deficit after SAH: lowers incidence of secondary ischemic events. - Cerebrovascular cognitive impairment: may improve cognitive function associated with chronic cerebral hypoperfusion.

Nimodipine may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Headache - Nausea - Flushing - Dizziness

Serious or Rare Side Effects: - Severe hypotension - Hepatic dysfunction - Severe allergic reaction (anaphylaxis)

When prescribing Nimodipine, clinicians should observe several precautionary measures to ensure patient safety.

- Monitor blood pressure: check for hypotension especially after initiation or dose changes. - Assess hepatic function: perform baseline liver enzymes and monitor periodically. - Review concomitant vasodilators: avoid additive hypotensive effects with other calcium channel blockers or nitrates. - Use caution in elderly patients: increased sensitivity to blood pressure drops and dizziness. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Nimodipine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other calcium channel blockers: combined use may cause profound hypotension. - Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase Nimodipine plasma levels, raising toxicity risk. - Nitrates: additive vasodilatory effect can lead to severe hypotension.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance bradycardia and hypotensive response. - Diuretics or other antihypertensives: require blood pressure monitoring and possible dose adjustment.